|
|
 |
|
Viewing report
|
|
|
|
Targeted Drug Delivery Technologies: Players, products & prospects to 2018 (Volume IV)
Espicom Business Intelligence Ltd, June 2009, Pages: 118
Targeted Delivery
By 2018, over 30 new products will be launched resulting in a global market for advanced targeted delivery products worth over US$8.5 billion.
Despite considerable advances in drug delivery technologies, there continues to be a high unmet clinical need for safer and better-tolerated drugs. Sub-optimal compliance and failure to persist with drug treatments are important determinants of therapeutic non-response and are of significant cost to healthcare providers. Advanced targeted drug delivery technologies will help to overcome some of these issues by improving pharmacokinetics, increasing tolerability and reducing dose-limiting off-target effects.
The need for targeted delivery platforms is increasing as patients and drug regulators seek to meet these challenges.
Current and future applications
Whilst the majority of targeted delivery systems under evaluation incorporate passive carrier systems, there will be a shift towards the use of actively targeted carriers to increase the therapeutic index of existing and new products. There are significant opportunities for future commercial developments within the pharmaceutical industry. These include:
Cost-effective production of antibodies and antibody fragments for drug targeting;
Development of new polymers and biopolymers that may be utilised in the safe and efficient targeted delivery of drugs and pro-drugs into host cells;
Development and selective targeting of macromolecules to improve intracellular uptake and tissue specificity;
Development of inactive pro-drugs for tissue specific release;
Extended product life-cycles through the development of targeted formulations;
Identification of new targeting ligands to improve the targeted delivery of small molecules and macromolecules;
Utilisation of multiple targeting ligands to address the needs of patient sub-types;
Combined technology platforms to develop targeted therapeutics and diagnostics in a single molecule.
A new generation of targeted delivery systems is under development to meet these needs which should provide greater control over the selective targeting of tissue, either with active moieties or inactive moieties which may be activated within the tissue by biological (enzymes), chemical (pH) or physical means (light, ultrasound) in order to release the active agent. The multitude of delivery platforms will lend themselves to the delivery of both small molecules and macromolecules and to a variety of target sites and delivery routes.
This report is part of a major new 4-volume strategic analysis
Drug Delivery Technologies:
Players, Products & Prospects to 2018
Focusing on the sectors that are driving growth
VOLUME I
CONTROLLED- RELEASE
VOLUME II
NANOTECHNOLOGY
VOLUME III
NUCLEIC ACID DELIVERY
VOLUME IV
TARGETED DELIVERY
Customers who bought this item also bought
Targeted Drug Delivery Analysis
Nanotechnology: Players, products & prospects to 2018 (Volume II)
Nucleic Acid Drug Delivery Technologies: Players, products & prospects to 2018 (Volume III)
Drug Delivery Technologies: Players, products & prospects to 2018
Drug Delivery in Cancer - Technologies, Markets and Companies
Emerging Drug Delivery Technologies & Strategies - Players, Pipelines & Partnerships
Controlled-release: Players, products & prospects to 2018 (Volume I)
Drug Delivery in Central Nervous System Diseases - Technologies, Markets and Companies
Nanoparticle Drug Delivery Market Report
Drug Delivery Technology - Revolutionizing Cancer Therapies
|
|
|
|
